Indolin-2-one p38α inhibitors II: Lead optimisation

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 18, 2011, Pages 5270-5273

  Eastwood, Paul ^a   González, Jacob ^a   Gómez, Elena ^a   Caturla, Francisco ^a   Balagué, Cristina ^a   Orellana, Adelina ^a   Domínguez, María ^a  

^a Almirall Prodesfarma S A   (Spain)

Author keywords

Indolin 2 ones; p38 Inhibitors

Indexed keywords

INDOLIN 2 ONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; NONHUMAN; RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR STRUCTURE; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 80051926925     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.07.033     Document Type: Article

References (16)

1. S. Kumar, J. Boehm, and J.C. Lee Nat. Rev. Drug Disc. 2 2003 717
2. P. Eastwood, J. González, E. Gómez, B. Vidal, F. Caturla, R. Roca, C. Balagué, A. Orellana, and M. Domínguez Bioorg. Med. Chem. Lett. 21 2011 4310
3. Data from MS/MS studies was used in the structural identification of all metabolites.
4. Full details for all biological assays can be found in Ref. 2 or references cited therein.
5. For further discussion see: M.J. Waring Expert Opin. Drug Disc. 5 2010 235
6. R.J. Young, D.V.S. Green, C.N. Luscombe, and A.P. Hill Drug Discovery Today 2011 10.1016/j.drudis.2011.06.001
7. Full synthetic details can be found in the following patent: Eastwood, P. R.; Gonzalez, J.; Vidal, B.; Aguilar, N. PCT Int. Appl. WO2009124692, 2009.
8. For metallation and trapping of indolin-2-ones see: F.C. Stevens, W.E. Bloomquist, A.G. Borel, M.L. Cohen, C.A. Droste, M.L. Heiman, A. Kriauciunas, D.J. Sall, F.C. Tinsley, and C.D. Jesudason Bioorg. Med. Chem. Lett. 17 2007 6270
9. A. Fensome, R. Bender, J. Cohen, M.A. Collins, V.A. Mackner, L.L. Miller, J.W. Ullrich, R. Winneker, J. Wrobel, P. Zhang, Z. Zhang, and Y. Zhu Bioorg. Med. Chem. Lett. 12 2002 3487
10. Gonczi, C.; Csikos, E.; Hermecz, I.; Heja, G.; Illar, A.; Nagy, L.; Santa Csutor, A.; Simon, A.; Simon, K.; Smelko Esek, A.; Szomor, T.; Szvoboda, G., PCT Int. Appl. WO2001005760, 2001.
11. For discussions on the stereoselective reduction of similar spirocyclic ketones see: H. Venkatesan, M.C. Davis, Y. Altas, J.P. Snyder, and D.C. Liotta J. Org. Chem. 66 2001 3653
12. J. Halász, B. Podányi, A. Sánta-Csutor, Z. Böcskei, K. Simon, M. Hanusz, and I. Hermecz J. Mol. Struct. 654 2003 187
13. This whole blood assay was used in many p38α programmes to compare in-vitro potency against potency in a cellular system in a whole blood medium which takes into account other factors such as cell permeability (not likely to be a significant problem for the majority of compounds in this article as assessed by Caco-2 permeability experiments) and off-target binding including plasma protein binding. In regard to the latter factor, recent opinion would suggest that extreme caution should be taken when prioritizing compounds based on results from in-vitro assays which are adversely affected by the inclusion of plasma proteins because unbound plasma concentrations in-vivo are determined not by plasma protein binding but by intrinsic clearance after oral dosing. For further discussion see: X. Liu, C. Chen, and C.E.C.A. Hop Curr. Top. Med. Chem. 11 2011 450
14. D.A. Smith, L. Di, and E.H. Kerns Nat. Rev. Drug. Disc. 9 2010 929
15. R.W. Daisley, and J.R. Hanbali Synth. Commun. 11 1981 743
16. A. Marfat, and M.P. Carta Tetrahedron Lett. 28 1987 4027